Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc. exhibits a positive outlook due to potential upside drivers such as faster-than-expected spine market growth and higher sales in its Enabling Technologies segment, which could lead to improved margins. The company is currently trading below historical valuation levels, accompanied by impressive double-digit free cash flow growth and an 8% free cash flow yield, indicating a favorable risk/reward profile for investors. Despite a slight miss in 2Q25 base business results compared to consensus, there remains a projection of profit upside relative to increased future estimates, reinforcing confidence in the company's financial trajectory.

Bears say

Globus Medical Inc. faces significant headwinds that contribute to a negative outlook on its stock, including anticipated slower growth in the spine market and potential revenue dis-synergies stemming from the recent NuVasive merger. Concerns regarding the company's ability to maintain margin expansion are compounded by lower-than-expected sales in its Enabling Technologies segment and challenges in launching key products within the musculoskeletal solutions category. Additionally, there are risks associated with competitive dynamics in the spine market and potential delays in expanding into new areas, all of which could impact overall financial performance and growth rates.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.